By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AstraZeneca PLC 

15 Stanhope Gate

London  England  W1K 1LN  United Kingdom
Phone: 44-20-7304-5000 Fax: 44-20-7304-5151


SEARCH JOBS

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

YEAR FOUNDED:

1999

LEADERSHIP:

CEO: Pascal Soriot

CFO: Marc Dunoyer

CMO: Marc Dunoyer

CTO: Andrew Chen

CCO: Katarina Ageborg

CMO: Sean Bohen

CLINICAL TRIAL:

Please click here for clinical trial information.

JOB OPPORTUNITY:

Please click here for AstraZeneca job opportunities.

PRODUCTS:

AstraZeneca Medications

For more information, visit
www.astrazeneca.com and follow us on www.twitter.com/astrazeneca.

FOLLOW BLANK:





Key Statistics


Email:
Ownership: Public

Web Site: AstraZeneca PLC
Employees: 50,000 worldwide
Symbol: AZN
 









Company News
Heptares Collaboration With AstraZeneca PLC (AZN) Yields New Insights To Advance Drug Discovery In Pain, Cancer And Inflammation 4/27/2017 6:49:09 AM
AstraZeneca PLC (AZN) Dumps Two Drugs From Pipeline, Causing an Ex-Partner's Stock to Tank Some More 4/27/2017 6:23:13 AM
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed 4/26/2017 5:51:18 AM
AstraZeneca PLC (AZN)'s Cambridge Headcount Hits 2,000 as Its New HQ Hit Budget Woes 4/26/2017 5:45:57 AM
AstraZeneca PLC (AZN), Stanford Tie-Up Bankrolls Two New R&D Projects 4/21/2017 6:08:34 AM
Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC (AZN), Bristol-Myers Squibb (BMY) Drugs 4/10/2017 5:45:15 AM
Sosei Subsidiary Heptares To Receive $12 Million Milestone Payment From AstraZeneca PLC (AZN) 4/5/2017 8:08:53 AM
First Collaborative Definition Of Patient Centricity, Co-Created By AstraZeneca PLC (AZN) With Patients And Carers, Is Published In British Medical Journal 3/31/2017 6:44:54 AM
AstraZeneca PLC (AZN) Release: TAGRISSO (osimertinib) Receives U.S. FDA Full Approval 3/31/2017 6:25:12 AM
AstraZeneca PLC (AZN) Release: LYNPARZA (Olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit In BRCA-Mutated Ovarian Cancer As Maintenance Therapy 3/30/2017 11:06:54 AM
12345678910...
//-->